|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 83.23 EUR | -0.44% |
|
-3.39% | -11.21% |
| 09/12 | Guggenheim Downgrades Sanofi to Neutral From Buy | MT |
| 09/12 | US FDA launches fresh safety scrutiny of approved RSV therapies for infants | RE |
| Capitalization | 10TCr 12TCr 9.5TCr 8.85TCr 16TCr 10,59100Cr 18TCr 1,10200Cr 43TCr 5,02000Cr 44TCr 43TCr 18,49500Cr | P/E ratio 2025 * |
12.1x | P/E ratio 2026 * | 12.1x |
|---|---|---|---|---|---|
| Enterprise value | 11TCr 13TCr 11TCr 9.94TCr 18TCr 11,89400Cr 20TCr 1,23700Cr 48TCr 5,63800Cr 50TCr 49TCr 20,77200Cr | EV / Sales 2025 * |
2.62x | EV / Sales 2026 * | 2.39x |
| Free-Float |
87.31% | Yield 2025 * |
4.99% | Yield 2026 * | 5.16% |
Last Transcript: Sanofi
| 1 day | -0.44% | ||
| 1 week | -3.39% | ||
| Current month | -2.95% | ||
| 1 month | -2.59% | ||
| 3 months | +3.05% | ||
| 6 months | -4.85% | ||
| Current year | -11.21% |
| 1 week | 82 |  | 85.86 |
| 1 month | 82 | | 90.79 |
| Current year | 76.15 | | 110.88 |
| 1 year | 76.15 | | 110.88 |
| 3 years | 76.15 | | 110.88 |
| 5 years | 74.92 | | 110.88 |
| 10 years | 62.5 | | 110.88 |
| Manager | Title | Age | Since |
|---|---|---|---|
Paul Hudson
CEO | Chief Executive Officer | 58 | 01/09/2019 |
| Director of Finance/CFO | 63 | 01/04/2024 | |
Madeleine Roach
COO | Chief Operating Officer | 41 | 01/10/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Patrick Kron
BRD | Director/Board Member | 72 | 01/05/2014 |
| Director/Board Member | 60 | 30/04/2019 | |
Paul Hudson
BRD | Director/Board Member | 58 | 30/10/2019 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 3.66% | 150 M€ | +17.74% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.44% | -3.39% | -9.36% | -6.20% | 12TCr | |
| -1.54% | -6.11% | +22.23% | +172.09% | 89TCr | |
| -0.82% | -2.66% | +33.66% | +13.78% | 49TCr | |
| -0.06% | -0.62% | +26.29% | +36.75% | 39TCr | |
| -0.76% | +0.64% | +22.59% | +3.51% | 34TCr | |
| +0.10% | -1.51% | +27.00% | +19.71% | 28TCr | |
| +0.17% | +0.58% | +19.51% | +24.96% | 25TCr | |
| -2.06% | -4.10% | -6.65% | -10.93% | 25TCr | |
| +0.07% | -2.56% | -61.75% | -35.08% | 21TCr | |
| -2.30% | -7.24% | +13.05% | +12.63% | 17TCr | |
| Average | -0.90% | -2.54% | +8.66% | +23.12% | 33.87TCr | |
| Weighted average by Cap. | -1.04% | -2.82% | +15.78% | +52.99% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 4.35TCr 5.06TCr 4.08TCr 3.8TCr 7TCr 4,54500Cr 7.6TCr 47TCr 18TCr 2,15400Cr 19TCr 19TCr 7,93700Cr | 4.65TCr 5.41TCr 4.36TCr 4.06TCr 7.48TCr 4,86100Cr 8.13TCr 51TCr 20TCr 2,30400Cr 20TCr 20TCr 8,48800Cr |
| Net income | 833.34Cr 969.91Cr 781.81Cr 728.49Cr 1.34TCr 87TCr 1.46TCr 9.07TCr 3.52TCr 41TCr 3.64TCr 3.56TCr 1,52200Cr | 831.85Cr 968.17Cr 780.41Cr 727.18Cr 1.34TCr 87TCr 1.46TCr 9.05TCr 3.52TCr 41TCr 3.63TCr 3.56TCr 1,51900Cr |
| Net Debt | 1.25TCr 1.45TCr 1.17TCr 1.09TCr 2.01TCr 1,30300Cr 2.18TCr 14TCr 5.27TCr 62TCr 5.44TCr 5.33TCr 2,27600Cr | 990.81Cr 1.15TCr 929.54Cr 866.14Cr 1.6TCr 1,03600Cr 1.73TCr 11TCr 4.19TCr 49TCr 4.33TCr 4.24TCr 1,80900Cr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/25/09 | 83.23 € | -0.44% | 19,37,799 |
| 08/25/08 | 83.60 € | -1.65% | 19,12,105 |
| 05/25/05 | 85.00 € | +0.51% | 20,04,635 |
| 04/25/04 | 84.57 € | -1.25% | 22,17,125 |
| 03/25/03 | 85.64 € | -0.59% | 14,47,788 |
Real-time Euronext Paris, December 09, 2025 at 10:25 pm IST
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- SAN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition